2型糖尿病合并非酒精性脂肪性肝病患者血尿酸水平变化及临床意义

肝脏 ›› 2023, Vol. 28 ›› Issue (12): 1476-1479.

2型糖尿病合并非酒精性脂肪性肝病患者血尿酸水平变化及临床意义

熊琦君, 朱雯

214000 江苏无锡市中医医院检验科

收稿日期:2023-05-28 出版日期:2023-12-31 发布日期:2024-03-01
通讯作者: 朱雯
基金资助:
无锡市中医医院院内项目(ZYYYB21012)

Changes and clinical significance of serum uric acid level in type 2 diabetes patients with nonalcoholic fatty liver disease

XIONG Qi-jun, ZHU Wen

Department of Laboratory,Wuxi Traditional Chinese Medicine Hospital, Jiangsu 214000, China

Received:2023-05-28 Online:2023-12-31 Published:2024-03-01
Contact: ZHU Wen

摘要/Abstract

摘要： 目的观察血尿酸水平在2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者中的变化,并分析其临床意义。方法选取无锡市中医医院2020年12月至2022年12月收治的T2DM患者118例,按照是否并发NAFLD分为合并组(n=88)与非合并组(n=30)。logistic回归分析T2DM合并NAFLD的影响因素。结果合并组、非合并组BMI为(26.72±2.53)kg/m²、(23.31±2.17)kg/m²,差异有统计学意义(P<0.05);合并组空腹血糖、HOMA-IR为(8.82±1.45)mmol/L、(3.58±0.95)mmol/L,均高于非合并组的(7.67±1.23)mmol/L、(3.05±0.79)mmol/L,(P<0.05);合并组ALT、AST、总胆固醇、三酰甘油及LDL为(37.94±2.68)U/L、(29.20±2.61)U/L、(5.38±1.13)mmol/L、(2.46±0.64)mmol/L及(3.31±0.80)mmol/L,均高于非合并组的(23.27±2.16)U/L、(21.71±2.03)U/L、(4.34±1.02)mmol/L、(1.32±0.55)mmol/L及(2.56±0.62)mmol/L;合并组血尿酸为(349.14±28.45)μmol/L,高于非合并组的(273.34±17.29)μmol/L,(P<0.05);合并组LDL为(1.35±0.38)mmol/L,低于非合并组的(2.29±0.43)mmol/L,(P<0.05)。多因素分析结果提示BMI、HOMA-IR以及血尿酸是T2DM并发NAFLD的危险因素(OR值分别为4.604、5.150、4.978,P<0.05)。结论 T2DM患者可能并发NAFLD,BMI、HOMA-IR以及血尿酸为其主要危险因素。

关键词: T2DM, NAFLD, 血尿酸

Abstract: Objective To observe the variations in serum uric acid levels among patients with type 2 diabetes mellitus(T2DM) and nonalcoholic fatty liver disease(NAFLD) and assess its clinical implications.Methods Between December 2020 and December 2022, 118 patients with T2DM admitted to our hospital were selected, including 64 males and 54 females, aged (57.78±4.07) years. Based on the presence or absence of NAFLD complications, patients were divided into combined group (n=88) and non-combined group (n=30). A retrospective study was carried out. Variables showing statistical differences were subjected to multivariate Logistic regression analysi.Results The BMI for the combined group was (26.72±2.53) kg/m², while it was (23.31±2.17) kg/m² for the non-combined group. The difference was statistically significant (P<0.05). The fasting blood glucose and HOMA-IR levels in the combined group were (8.82±1.45) mmol/L and (3.58±0.95), respectively, which were significantly higher than those in the non-combined group [(7.67±1.23) mmol/L and (3.05±0.79), P<0.05]. The levels of ALT, AST, total cholesterol, triglyceride and LDL in the combined group were (37.94±2.68) U/L, (29.20±2.61) U/L, (5.38±1.13) mmol/L, (2.46±0.64) mmol/L and (3.31±0.80) mmol/L, respectively. In comparison, the non-combined group had values of (23.27±2.16) U/L, (21.71±2.03) U/L, (4.34±1.02) mmol/L, (1.32±0.55) mmol/L and (2.56±0.62) mmol/L. The difference between the groups was statistically significant (P<0.05). The serum uric acid in the combined group was (349.14±28.45) μmol/L, compared to (273.34±17.29) μmol/L in the non-combined group, and the difference was statistically significant (P<0.05) . Additionaly, the LDL level in the combined group was (1.35±0.38) mmol/L, which was significantly lower than the (2.29±0.43) mmol/L observed in the non-combined group(P<0.05). According to the multivariate Logistic regression analysis, when incorporating the above differences into the study, it was suggested that BMI, HOMA-IR and serum uric acid were risk factors for T2DM complicated with NAFLD (OR values were 4.604, 5.150 and 4.978, respectively, P<0.05).Conclusion Patients with T2DM may also present with complications related to NAFLD. BMI, HOMA-IR and serum uric acid are the main risk factors that warreant greater attention in clinical settings.

Key words: Type 2 diabetes, Nonalcoholic fatty liver disease, Blood uric acid

熊琦君, 朱雯. 2型糖尿病合并非酒精性脂肪性肝病患者血尿酸水平变化及临床意义[J]. 肝脏, 2023, 28(12): 1476-1479.

XIONG Qi-jun, ZHU Wen. Changes and clinical significance of serum uric acid level in type 2 diabetes patients with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2023, 28(12): 1476-1479.

参考文献

[1] 蔡勇, 李璟, 欧琴. T2DM合并NAFLD患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[2] Kuchay M S, Krishan S, Mishra S K, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)[J]. Diabetes Care, 2018, 41(8): 1801-1808.
[3] 黄晓梅, 徐聪聪, 黄懂忆, 等. NAFLD合并T2DM的研究进展[J]. 南昌大学学报(医学版), 2019, 59(4): 97-99.
[4] 赵晓春, 钟庆, 刘书宏, 等. NAFLD并发T2DM患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.
[5] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. T2DM基层诊疗指南(实践版·2019)[J]. 中华全科医师杂志, 2019, 18(9): 810-818.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. NAFLD诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 163-166.
[7] Horáková D, Štěpánek L, Janout V, et al. Optimal homeostasis model assessment of insulin resistance cut-offs: a cross-sectional study in the Czech population[J]. Medicina, 2019, 55:158.
[8] 汪运生, 戴武. NAFLD与T2DM关系的研究进展[J]. 安徽医学, 2019, 40(3): 339-342.
[9] Barb D, Repetto E M, Stokes M E, et al. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease[J]. Obesity, 2021, 29(11): 1950-1960.
[10] 李小林, 何伟, 刘盛扶. 老年T2DM患者中NAFLD与代谢性指标的相关性[J]. 实用预防医学, 2022, 29(2): 145-148.
[11] 刘佼, 任彩琴, 冯亚莉, 等. T2DM合并NAFLD患者肝纤维化与胰岛素抵抗的关系[J]. 中国临床研究, 2021, 34(4): 443-448.
[12] 王东旭, 南楠, 邴浩, 等. 甘油三酯葡萄糖乘积指数与BMI对T2DM合并NAFLD的预测价值[J]. 临床肝胆病杂志, 2022, 38(5): 1064-1068.
[13] 李华, 朱宏伟, 李志辉. T2DM合并代谢相关脂肪性肝病患者胎球蛋白A水平与胰岛素抵抗的相关性研究[J]. 中国糖尿病杂志, 2021, 29(7): 492-496.
[14] 王福慧, 侯瑞田, 山秀杰, 等. 血清可溶性CD36及尿酸与T2DM合并NAFLD相关性[J]. 中华实用诊断与治疗杂志, 2018, 32(1): 87-90.
[15] Li S, Fu Y, Liu Y, et al. Serum uric acid levels and nonalcoholic fatty liver disease: a 2-sample bidirectional mendelian randomization study[J]. J Clin Endocr Metab, 2022, 107(8): 3497-3503.